Search by category - Any -Regulated informationInside informationNon-regulated information Search by year - Any -2024202320222021202020192018201720162015 7 January 2019 Biocartis and Nichirei Bioscience Announce Commercialization Collaboration for Japanese Market Non-regulated information 3 December 2018 Genomic Health and Biocartis Expand Collaboration to Urology with the Development of an Idylla™ Oncotype DX Genomic Prostate Score® Test Non-regulated information 29 November 2018 Biocartis and AstraZeneca Enter Into Agreement Aimed at Faster Lung Cancer Biomarker Results Non-regulated information 1 November 2018 Eight Idylla™ Performance Studies to be Presented at the Association for Molecular Pathology Conference in the US Non-regulated information 19 October 2018 Studies on Idylla™ MSI and RAS liquid biopsy tests to be presented at ESMO congress Non-regulated information 28 August 2018 Biocartis Obtains Exclusive Worldwide License Rights for EGFR Ectodomain Mutations Determining Response to Targeted Colorectal Cancer Therapy Non-regulated information 31 July 2018 Study Abstract on Performance of Idylla™ RAS tests Selected for Oral Presentation at 70th AACC Annual Scientific Meeting in Chicago, IL (US) Non-regulated information 17 July 2018 Biocartis launches innovative Idylla™ MSI Assay Idylla™ MSI Assay further strengthens Biocartis’ test menu and offers opportunities to enter the immuno-oncology testing market Non-regulated information 27 June 2018 Study Reviewing 2,500 Performed Idylla™ Tests Shows Generation of Valid Results in 98.1% of Cases and Outperformance over Reference Methods Non-regulated information 28 May 2018 Study Demonstrates Ability of Idylla™ EGFR Mutation Test to Produce a Result in 80% of Failed Next Generation Sequencing Lung Cancer Tests Non-regulated information Pagination First page « First Previous page ‹‹ … Page 3 Page 4 Page 5 Page 6 Current page 7 Page 8 Page 9 Page 10 Page 11 Next page ›› Last page Last »